Topic

Mike Hennessy Jr. is the President and CEO of 

Articles

Pharma's ability to continually reinvent itself will be critical in growing future business operations.

Billions of Reasons to be Buoyant

Feliza Mirasol is the science editor for 

Danaher intends to acquire Abcam, a provider of life sciences assays and reagents, for $5.7 billion.

Danaher to Acquire Abcam in $5.7 Billion Deal

The deal is worth up to $36 million with an initial upfront consideration of $14 million, with an additional $22 million in contingent value rights (CVRs) that is payable upon achieving certain milestones.

LEO Pharma to Acquire Timber Pharmaceuticals

Zygel is the first and only pharmaceutically manufactured, synthetic cannabidiol that is formulated as a patient-protected permeation-enhanced gel for transdermal delivery.

Harmony Biosciences to Acquire Zynerba Pharmaceuticals

The acquisition of the latter includes the company’s lead development asset INV-202, an oral CB1 inverse agonist which is designed to block the receptor protein CB1. 

Novo Nordisk to Acquire Inversago Pharma

The completion of three acquisitions of Versanis Bio, Sigilon Therapeutics, and DICE Therapeutics boosts Eli Lilly and Company’s product pipeline in obesity, diabetes, and immunology.

Lilly Completes Spate of Acquisitions

Novartis has completed its acquisition of biopharma company Chinook Therapeutics.  

Novartis Finalizes Chinook Therapeutics Acquisition in Deal Worth Up to $3.5 Billion

The initial collaboration between the two companies began in 2017 with an extension announced in 2021.

Regeneron Pharmaceuticals to Acquire Decibel Therapeutics 

BlueRock will be responsible for the global development and commercialization of therapeutic candidates emerging from this collaboration.

BlueRock Therapeutics and bit.bio Collaborate for Manufacture of Regulatory T cell Based Therapies

Biogen’s acquisition of Reata will grant them access to Reata’s FDA-approved treatment for Friedreich’s ataxia.

Mergers and Acquisitions